Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicus Pharma Ltd. SEC filings document material-event reporting for a clinical-stage life sciences and biotechnology company incorporated in Ontario. The filings identify the company's one-segment operating model and record capital-structure activity involving common shares, shelf registration statements, at-the-market offering arrangements and a standby equity purchase agreement.
Recent Form 8-K disclosures also cover unregistered equity sales, debenture financing with subsidiary guaranties, debt repayment mechanics, amendments to equity distribution agreements and listing-compliance notices. These filings frame the company's financing arrangements, governance obligations, securities registration activity and exchange-status disclosures.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and are scheduled to expire on March 27, 2031. Following this award, he holds 25,000 derivative securities linked to Common Shares.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and are scheduled to expire on March 27, 2031. Following this award, he holds 25,000 derivative securities linked to Common Shares.
Medicus Pharma Ltd. director Robert J. Ciaruffoli reported receiving a grant of stock options covering 25,000 underlying Common Shares. The options have a conversion price of $0.50 per share, are exercisable beginning on March 26, 2027, and expire on March 27, 2031. Following this award, he holds 25,000 stock options directly.
Medicus Pharma Ltd. director Robert J. Ciaruffoli reported receiving a grant of stock options covering 25,000 underlying Common Shares. The options have a conversion price of $0.50 per share, are exercisable beginning on March 26, 2027, and expire on March 27, 2031. Following this award, he holds 25,000 stock options directly.
Medicus Pharma Ltd. Chief Scientific Officer Brennan Edward J. received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share and expire on March 27, 2031. Following this award, he holds 25,000 options directly.
Medicus Pharma Ltd. Chief Scientific Officer Brennan Edward J. received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share and expire on March 27, 2031. Following this award, he holds 25,000 options directly.
Medicus Pharma Ltd. reported that President and CFO Carolyn F. Bonner received a grant of stock options as equity compensation. She was awarded options for 100,000 Common Shares at an exercise price of $0.50 per share, giving her the right to buy shares at that price in the future.
The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, Bonner holds stock options covering 100,000 shares. This is an acquisition of derivative securities, not an open‑market purchase or sale of the company’s stock.
Medicus Pharma Ltd. reported that President and CFO Carolyn F. Bonner received a grant of stock options as equity compensation. She was awarded options for 100,000 Common Shares at an exercise price of $0.50 per share, giving her the right to buy shares at that price in the future.
The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, Bonner holds stock options covering 100,000 shares. This is an acquisition of derivative securities, not an open‑market purchase or sale of the company’s stock.
Medicus Pharma Ltd. Chief Executive Officer Raza Bokhari received a grant of stock options for 325,000 Common Shares. The options have an exercise price of $0.50 per share and were awarded at no cost on the grant date.
The options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031 if not exercised. Following this grant, Bokhari holds stock options covering a total of 325,000 underlying Common Shares directly as reported in this filing.
Medicus Pharma Ltd. Chief Executive Officer Raza Bokhari received a grant of stock options for 325,000 Common Shares. The options have an exercise price of $0.50 per share and were awarded at no cost on the grant date.
The options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031 if not exercised. Following this grant, Bokhari holds stock options covering a total of 325,000 underlying Common Shares directly as reported in this filing.
Medicus Pharma Ltd. director Ashton William received a grant of stock options, giving him the right to acquire 25,000 common shares. The options have an exercise price of $0.50 per share and expire in 2031. Following this compensation award, he holds options covering 25,000 shares directly.
Medicus Pharma Ltd. director Ashton William received a grant of stock options, giving him the right to acquire 25,000 common shares. The options have an exercise price of $0.50 per share and expire in 2031. Following this compensation award, he holds options covering 25,000 shares directly.
Medicus Pharma Ltd. has filed Post-Effective Amendment No. 1 converting its earlier Form S-1 into a Form S-3 and keeping available for resale up to 1,397,184 common shares held by selling shareholders. The company states it will receive no proceeds from those resale transactions.
The prospectus incorporates the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and discloses that 39,362,109 common shares were outstanding as of March 17, 2026. The filing also summarizes the August 29, 2025 acquisition of Antev for approximately $2.97 million in cash plus 1,603,164 consideration shares and describes contractual staggered lock-up releases for the consideration shares.
Medicus Pharma Ltd. registers up to 7,500,000 common shares via a prospectus supplement to its effective Registration Statement on Form S-1.
The supplement incorporates the Company’s Form 10-K filed March 25, 2026, and notes 39,362,109 common shares outstanding as of March 17, 2026. The Company’s common shares trade on Nasdaq under the symbol MDCX; the last reported sales price on March 24, 2026 was $0.49.
Medicus Pharma Ltd. is a clinical-stage biotech company developing two main assets: SkinJect’s doxorubicin-containing microneedle array (D‑MNA) for non‑melanoma skin cancers and Antev’s Teverelix, a long‑acting GnRH antagonist for advanced prostate cancer and acute urinary retention.
The company completed a reverse takeover of SkinJect in 2023, listed on Nasdaq in 2024, and voluntarily delisted from the TSX Venture Exchange in 2025. As of March 17, 2026, it had 39,362,109 common shares outstanding and a non‑affiliate market value of about $28.3 million as of June 30, 2025.
SkinJect’s Phase 1 trial met safety and secondary efficacy endpoints, and a 90‑patient Phase 2 study (SKNJCT‑003) in nodular BCC has completed enrollment, with topline data showing the 200 µg dose achieving 73% clinical and 40% histological clearance at Day 57. A UAE Phase 2 trial (SKNJCT‑004) is also underway.
In August 2025, Medicus acquired 98.6% of Antev for roughly $2.97 million in cash plus 1,603,164 shares, with up to $65 million in contingent FDA milestone payments. Teverelix holds composition and process patents out to 2039 and beyond, with FDA‑cleared Phase 2b programs in both advanced prostate cancer and acute urinary retention.
Medicus maintains extensive microneedle IP licensed from the University of Pittsburgh, global Teverelix patents, and several non‑binding collaborations, including with HelixNano on mRNA‑based vaccines and Reliant AI on AI‑driven clinical development. The company has 16 full‑time employees and qualifies as an emerging growth and smaller reporting company, allowing scaled U.S. disclosure requirements.
Medicus Pharma Ltd. is a clinical-stage biotech company developing two main assets: SkinJect’s doxorubicin-containing microneedle array (D‑MNA) for non‑melanoma skin cancers and Antev’s Teverelix, a long‑acting GnRH antagonist for advanced prostate cancer and acute urinary retention.
The company completed a reverse takeover of SkinJect in 2023, listed on Nasdaq in 2024, and voluntarily delisted from the TSX Venture Exchange in 2025. As of March 17, 2026, it had 39,362,109 common shares outstanding and a non‑affiliate market value of about $28.3 million as of June 30, 2025.
SkinJect’s Phase 1 trial met safety and secondary efficacy endpoints, and a 90‑patient Phase 2 study (SKNJCT‑003) in nodular BCC has completed enrollment, with topline data showing the 200 µg dose achieving 73% clinical and 40% histological clearance at Day 57. A UAE Phase 2 trial (SKNJCT‑004) is also underway.
In August 2025, Medicus acquired 98.6% of Antev for roughly $2.97 million in cash plus 1,603,164 shares, with up to $65 million in contingent FDA milestone payments. Teverelix holds composition and process patents out to 2039 and beyond, with FDA‑cleared Phase 2b programs in both advanced prostate cancer and acute urinary retention.
Medicus maintains extensive microneedle IP licensed from the University of Pittsburgh, global Teverelix patents, and several non‑binding collaborations, including with HelixNano on mRNA‑based vaccines and Reliant AI on AI‑driven clinical development. The company has 16 full‑time employees and qualifies as an emerging growth and smaller reporting company, allowing scaled U.S. disclosure requirements.
Medicus Pharma Ltd. reported that it sold a total of 4,471,038 common shares to YA II PN, Ltd. (Yorkville) under a previously disclosed Standby Equity Purchase Agreement. These unregistered sales, completed between December 19, 2025 and March 6, 2026, generated approximate aggregate consideration of $3,846,910.
The company has used part of the net proceeds to prepay a portion of an outstanding debenture held by Yorkville, reducing that obligation. The shares were issued in private transactions relying on the Section 4(a)(2) exemption from registration, and Yorkville may resell them under an effective registration statement while Medicus may request additional share purchases under the SEPA, subject to its conditions and limitations.
Medicus Pharma Ltd. reported that it sold a total of 4,471,038 common shares to YA II PN, Ltd. (Yorkville) under a previously disclosed Standby Equity Purchase Agreement. These unregistered sales, completed between December 19, 2025 and March 6, 2026, generated approximate aggregate consideration of $3,846,910.
The company has used part of the net proceeds to prepay a portion of an outstanding debenture held by Yorkville, reducing that obligation. The shares were issued in private transactions relying on the Section 4(a)(2) exemption from registration, and Yorkville may resell them under an effective registration statement while Medicus may request additional share purchases under the SEPA, subject to its conditions and limitations.